Compare Manchester United PLC (MANU) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manchester United PLC vs Spyre Therapeutics Inc. Common Stock — how do they compare? Manchester United PLC trades at $20.68 (market cap $3.55B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 2.1× Manchester United PLC's market cap, and Manchester United PLC pays a 1.26% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Manchester United PLC for 109 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| MANU | SYRE | |
|---|---|---|
Market Cap | $3.55B | $7.35B |
Volume | 311,271 | 1,624,631 |
Sector | Media | Health |
52-Week High | $24.19 | $108.92 |
52-Week Low | $15.20 | $22.18 |
Typical Hold Time | 109 Days | 0 Days |
Enterprise Value | $4.38B | $6.35B |
Dividend Yield | 1.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manchester United (MANU) trades at $21.08, up 1.2% with a bullish technical signal despite negative profitability metrics. The stock shows mixed earnings performance with recent beats but negative net income margins. Revenue reached $666.51M in 2025, though the company continues to post losses. Analyst sentiment is divided with 40% buy ratings, while technical indicators suggest potential near-term support at $21.
The investment case hinges on franchise valuation upside versus operational challenges. While trading at a discount to Forbes' $7.2B valuation estimate, persistent losses and high debt levels present significant risks. Champions League qualification offers revenue potential, but profitability remains elusive amid competitive pressures in European football.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
